000284605 001__ 284605
000284605 005__ 20240229155053.0
000284605 0247_ $$2doi$$a10.1016/j.euo.2023.09.008
000284605 0247_ $$2pmid$$apmid:37806841
000284605 0247_ $$2altmetric$$aaltmetric:155203594
000284605 037__ $$aDKFZ-2023-02025
000284605 041__ $$aEnglish
000284605 082__ $$a610
000284605 1001_ $$0P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aKrilaviciute, Agne$$b0$$eFirst author$$udkfz
000284605 245__ $$aDigital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.
000284605 260__ $$aAmsterdam$$bElsevier$$c2023
000284605 3367_ $$2DRIVER$$aarticle
000284605 3367_ $$2DataCite$$aOutput Types/Journal article
000284605 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1702549363_27018
000284605 3367_ $$2BibTeX$$aARTICLE
000284605 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284605 3367_ $$00$$2EndNote$$aJournal Article
000284605 500__ $$a#EA:C130#LA:C130#LA:C020# / 2023 Dec;6(6):566-573
000284605 520__ $$aAnnual digital rectal examination (DRE) is recommended as a stand-alone screening test for prostate cancer (PCa) in Germany for 45+ yr olds. DRE diagnostic performance in men as young as 45 yr old has not been proved by a screening trial.To determine DRE diagnostic performance in a screening trial.This analysis was conducted within the multicentric, randomized PROBASE trial, which enrolled >46 000 men at age 45 to test risk-adapted prostate-specific antigen (PSA) screening for PCa.(1) DRE was analyzed as a one-time, stand-alone screening offer at age 45 in 6537 men in one arm of the trial and (2) PCa detection by DRE was evaluated at the time of PSA-screen-driven biopsies (N = 578).(1) True-/false-positive detection rates of DRE as compared with PSA screening and (2) DRE outcome at the time of a prostate biopsy were evaluated.(1) A prospective analysis of 57 men with suspicious DRE at age 45 revealed three PCa. Detection rate by DRE was 0.05% (three of 6537) as compared with a four-fold higher rate by PSA screening (48 of 23 301, 0.21%). The true-positive detection rate by DRE relative to screening by PSA was 0.22 (95% confidence interval [CI] = [0.07-0.72]) and the false-positive detection rate by DRE was 2.2 (95% CI = [1.50-3.17]). (2) Among PSA-screen-detected PCa cases, 86% had unsuspicious DRE (sensitivity relative to PSA was 14%), with the majority of these tumors (86%) located in the potentially accessible zones of the prostate as seen by magnetic resonance imaging.The performance of stand-alone DRE to screen for PCa is poor. DRE should not be recommended as a PCa screening test in young men. Furthermore, DRE does not improve the detection of PSA-screen-detected PCa.Our report demonstrated the poor diagnostic performance of digital rectal examination in the screening for prostate cancer in young men.
000284605 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000284605 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284605 650_7 $$2Other$$aDigital rectal examination
000284605 650_7 $$2Other$$aProstate cancer
000284605 650_7 $$2Other$$aScreening
000284605 7001_ $$0P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aBecker, Nikolaus$$b1$$eFirst author$$udkfz
000284605 7001_ $$aLakes, Jale$$b2
000284605 7001_ $$aRadtke, Jan Philipp$$b3
000284605 7001_ $$aKuczyk, Markus$$b4
000284605 7001_ $$aPeters, Inga$$b5
000284605 7001_ $$aHarke, Nina N$$b6
000284605 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b7$$udkfz
000284605 7001_ $$aKoerber, Stefan A$$b8
000284605 7001_ $$aHerkommer, Kathleen$$b9
000284605 7001_ $$aGschwend, Jürgen E$$b10
000284605 7001_ $$aMeissner, Valentin H$$b11
000284605 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b12$$udkfz
000284605 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b13$$udkfz
000284605 7001_ $$aKristiansen, Glen$$b14
000284605 7001_ $$0P:(DE-HGF)0$$aHadaschik, Boris$$b15
000284605 7001_ $$aArsov, Christian$$b16
000284605 7001_ $$aSchimmöller, Lars$$b17
000284605 7001_ $$aGiesel, Frederik Lars$$b18
000284605 7001_ $$aAntoch, Gerald$$b19
000284605 7001_ $$aMakowski, Marcus$$b20
000284605 7001_ $$aWacker, Frank$$b21
000284605 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b22$$udkfz
000284605 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b23$$eLast author$$udkfz
000284605 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b24$$eLast author$$udkfz
000284605 773__ $$0PERI:(DE-600)2945338-0$$a10.1016/j.euo.2023.09.008$$gp. S2588931123002031$$n6$$p566-573$$tEuropean urology oncology$$v6$$x2588-9311$$y2023
000284605 909CO $$ooai:inrepo02.dkfz.de:284605$$pVDB
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000284605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000284605 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000284605 9141_ $$y2023
000284605 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL ONCOL : 2022$$d2023-08-25
000284605 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000284605 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000284605 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000284605 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000284605 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000284605 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000284605 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000284605 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR UROL ONCOL : 2022$$d2023-08-25
000284605 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000284605 9202_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x1
000284605 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000284605 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x1
000284605 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000284605 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x3
000284605 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x4
000284605 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x5
000284605 9200_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000284605 980__ $$ajournal
000284605 980__ $$aVDB
000284605 980__ $$aI:(DE-He78)C130-20160331
000284605 980__ $$aI:(DE-He78)E050-20160331
000284605 980__ $$aI:(DE-He78)C060-20160331
000284605 980__ $$aI:(DE-He78)ED01-20160331
000284605 980__ $$aI:(DE-He78)E010-20160331
000284605 980__ $$aI:(DE-He78)C020-20160331
000284605 980__ $$aUNRESTRICTED